Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
Güner et al.,
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir,..,
Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Retrospective 824 hospitalized patients in Turkey showing lower ICU admission for HCQ vs. favipiravir.
risk of ICU admission, 77.3% lower, RR 0.23, p = 0.16, treatment 604, control 100, inverted to make RR<1 favor treatment, IPTW multivariate analysis, HCQ vs. favipiravir.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Güner et al., 29 Dec 2020, retrospective, Turkey, peer-reviewed, 23 authors.
Abstract: Journal of Infection and Public Health 14 (2021) 365–370
Contents lists available at ScienceDirect
Journal of Infection and Public Health
journal homepage: http://www.elsevier.com/locate/jiph
Comparing ICU admission rates of mild/moderate COVID-19 patients
treated with hydroxychloroquine, favipiravir, and
hydroxychloroquine plus favipiravir
Rahmet Guner a , Imran Hasanoglu a,∗ , Bircan Kayaaslan a , Adalet Aypak b , Esragul Akinci c ,
Hurrem Bodur c , Fatma Eser a , Ayse Kaya Kalem a , Orhan Kucuksahin d , Ihsan Ates e ,
Aliye Bastug c , Yasemin Tezer Tekce b , Zeynep Bilgic b , Fahriye Melis Gursoy b ,
Hatice Nisa Akca b , Seval Izdes f , Deniz Erdem g , Emra Asfuroglu e , Habibe Hezer h ,
Hatice Kilic i , Musa Cıvak e , Sibel Aydogan j , Turan Buzgan a
a
Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey
c
Department of Infectious Disease and Clinical Microbiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
d
Department of Rheumatology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
e
Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
f
Department of Anaesthesiology and Reanimation, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
g
Department of Anaesthesiology and Reanimation, Ankara City Hospital, Ankara, Turkey
h
Department of Pulmonary Diseases, Ankara City Hospital, Ankara, Turkey
i
Department of Pulmonary Diseases, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
j
Department of Virology, Ankara City Hospital, Ankara, Turkey
b
a r t i c l e
i n f o
Article history:
Received 11 November 2020
Received in revised form
10 December 2020
Accepted 15 December 2020
Keywords:
COVID-19
Treatment
Favipiravir
Hydroxychloroquine
ICU
a b s t r a c t
Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized
mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus
favipiravir.
Methods: Single center retrospective designed observational study conducted in Ankara City Hospital.
Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics
with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of
treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences
in several variables on admission.
Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824
were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%)
of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841
to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to
0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all
the covariates in the planned propensity score had weighted standardized effect sizes below 10% which
were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment)
was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus
favipiravir treatment. After using combination of SMOTE..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit